EMP-01 safety and dose study for social anxiety
About this title
Read the official source — NCT06693609Researchers compared EMP-01 and placebo, tracking side effects to assess safety and tolerability in adults with an anxiety condition.
Understand this study
What did researchers investigate?
Researchers compared EMP-01 and placebo, tracking side effects to assess safety and tolerability in adults with an anxiety condition.
Who was this study for?
This study was for people with anxiety. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Bridgetown and 6 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
- Recruitment status
- Completed
- Enrollment listed in the registry
- 70
- Sponsor
- atai Therapeutics, Inc.
- Sponsor type
- Biotech company
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United Kingdom
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT06693609
- Official title
Show the full official title
A Phase 2a, Exploratory, Randomized, Double-Blind, Placebo-Controlled Trial of the Safety, Tolerability, and Efficacy of EMP-01 in Adult Participants With Social Anxiety Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
Bridgetown · Manchester · Blackpool
4 more locations
- Liverpool
- Tankersley
- Thornaby
- Leeds
Interested in joining this study?
Questions about this study
What did researchers investigate?
Researchers compared EMP-01 and placebo, tracking side effects to assess safety and tolerability in adults with an anxiety condition.
Who is behind this study?
The study sponsor is atai Therapeutics, Inc.
Did this study involve medication?
Yes. The study involved medication, including EMP-01 and EMP-01 Placebo.
Who was this study for?
This study was for people with anxiety. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
